Akari Therapeutics Plc (AKTX) Financial Statements
Free cash flow over the same period: -$10.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AKTXAkari Therapeutics PlcFollow AKTX — free
—
Price chart with a free account
- Market cap
- 640.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2006 Dec 06 | FY2007 Dec 07 | FY2008 Dec 08 | FY2009 Dec 09 | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | — | — | — | — | — | — | 1.5 | 1.3 | 1.6 | 5.8 | 17.3 | 23.3 | 11.8 | 8.7 | 8.8 | 9.1 | 9.6 | 5.5 | 7.0 | 2.8 | 4.9 | |
| Operating income | — | — | — | — | — | — | -3.7 | -3.6 | -1.9 | -30.6 | -27.2 | -37.8 | -20.8 | -17.0 | -18.0 | -17.2 | -23.1 | -16.8 | -21.6 | -17.3 | -31.0 | |
| Pre-tax income | — | — | — | — | — | — | — | — | -1.9 | -45.3 | -18.1 | -35.4 | -20.5 | -16.8 | -17.1 | -17.4 | -0.0 | -10.0 | -19.8 | -18.3 | -32.8 | |
| Income tax | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.0 | -1.9 | |
| Net income | -1.8 | -3.1 | -1.4 | -1.0 | -0.7 | -2.1 | -4.3 | -3.6 | -1.9 | -45.3 | -18.1 | -35.4 | -20.5 | -16.8 | -17.1 | -17.4 | -17.7 | -10.0 | -19.8 | -17.3 | -31.0 | |
| Diluted EPS ($) | — | — | — | — | — | — | -0.35 | -0.17 | -0.02 | -0.05 | -0.02 | -0.03 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | |
| Diluted shares (mn) | — | — | — | — | — | — | — | — | 85.5 | 852.1 | 1177.7 | 1247.3 | 1540.3 | 1831.0 | 3159.0 | 4292.1 | 6243.5 | 9789.0 | 23888.0 | 67328.1 | — |
USD millions · SEC XBRL
Akari Therapeutics Plc — questions
- What is Akari Therapeutics Plc's net income?
- -$31.0M over the twelve months to 2026-06-30.
- What is Akari Therapeutics Plc's free cash flow?
- -$10.6M over the twelve months to 2026-06-30.
Every figure on this page comes from Akari Therapeutics Plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.